Neuroblastoma Market Size, Epidemiology, Drugs, Therapies, Leading Companies and Competitive Analysis by DelveInsight

Neuroblastoma Market

DelveInsight’sNeuroblastoma Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some facts of Neuroblastoma Market :

According to DelveInsight, total Incident population of Neuroblastoma in the seven major markets were observed to be more than 1,500 in 2017
DelveInsight’s estimate suggest higher incidence of neuroblastoma in the United States, as compared to EU-5 countries and Japan, with 629 Incident population in 2017. Furthermore, the incidence rate of neuroblastoma is increasing at a very slow rate in the United States, has stabilized in the EU5 and in decreasing in Japan for the forecasted period, i.e. 2017–2030.
As per DelveInsight’s analyst, among the European countries, France has the highest Incident population of Neuroblastoma with 156 cases, followed by the United Kingdom which has Incident population of 147 in 2017. On the other hand, Spain has the lowest Incident population of 90 cases in 2017.
Furthermore, according to DelveInsight’s analyst, Japan witnessed more than 250 incident cases of neuroblastoma in 2017.


Request Sample Report:


Scope of the Neuroblastoma Market Report

The Neuroblastoma report covers the descriptive overview of Neuroblastoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Neuroblastoma epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Neuroblastoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Neuroblastoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The Neuroblastoma report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuroblastoma market


Request Sample Report:


Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. “neuro” means nerves and “blastoma” refers to the tumor affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.

Stages of neuroblastoma determine the extent of spread of the tumor in the patients, and the disease is staged on the basis of results of physical exams, imaging tests, and biopsies of the main tumor and other tissues. Staging of neuroblastoma is based on two classification systems: International Neuroblastoma Staging System (INSS) and International Neuroblastoma Risk Group Staging System (INRGSS).

Neuroblastoma is most common in very young children, but it is rare in children over the age of 10 years.

Approximately 1% to 2% of patients with neuroblastoma inherit an increased risk of developing neuroblastoma from their parents.


Some of the Neuroblastoma companies:

Y-MABS Therapeutics Inc
Autolus Therapeutics
Clarity Pharmaceuticals
EUSA Pharma
United Therapeutics Corp
And Many Others


Neuroblastoma Drugs Covered:

And Many Others


Table of contents:

1. Key Insights

2. Executive Summary of Neuroblastoma

3. Competitive Intelligence Analysis for Neuroblastoma

4. Neuroblastoma: Market Overview at a Glance

5. Neuroblastoma: Disease Background and Overview

6. Patient Journey

7. Neuroblastoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Neuroblastoma Treatment

11. Marketed Products

12. Emerging Therapies

13. Neuroblastoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neuroblastoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States